Sanofi's profit rose on demand for its flu vaccines and a shot for a common respiratory virus, as well as further growth in its blockbuster skin and asthma therapy Dupixent.

Earnings per share excluding some items reached €2.86 ($3.10) in the third quarter, above analysts' estimates, helped by its influenza and respiratory syncytial virus shots that saw earlier-than-anticipated sales.